Syngene Intl CFO says 25-30% of clients seeking alternatives to China supply chains; co looking to diversify
Syngene: FY25 guidance intact as biotech funding revives
biologics Roundtable: the current landscape and future developments
The Role of Quality Management in Modern CRDMOs
BIOSECURE Act: Companies turn to US manufacturers
Indian CDMO Companies Must Level Up for Opportunity from US Biosecure Act
How Syngene Is Revving Up Capabilities In ADCs, PROTACs
Bharat Eyes Global Biomanufacturing Dominance: Boosting Innovation, Collaboration & Entrepreneurship with BioE3 Policy
Forging Ahead in Formulation
Syngene expands supply chain with China-free options
